Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

WVE-N531

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: dystrophin (DMD) · developed by Wave Life Sciences

Phase 1/2 Most advanced trial

WVE Developer

1 Registered trials

What is WVE-N531?

WVE-N531 is an antisense oligonucleotide designed to modulate dystrophin expression. It is being studied in Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Targets: dystrophin (DMD)
Mechanism: Gene silencing: dystrophin (DMD)
Therapy area: Neurology
Developer: Wave Life Sciences (WVE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04906460	Phase 1/2	Duchenne Muscular Dystrophy	Recruiting	WVE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular Dystrophy

Other drugs acting on DMD

WVE-210201 Phase 2/3

More from Wave Life Sciences

WVE-003 Phase 1/2 WVE-004 Phase 1/2 WVE-006 Phase 1/2 WVE-007 Phase 1/2 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2 WVE-210201 Phase 2/3

Sources

ClinicalTrials.gov NCT04906460

Updated Oct 3, 2026. Something wrong or missing? Report it on the WVE page.

Follow WVE, the company behind WVE-N531

See WVE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

WVE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z